

INTERNATIONAL ISOTOPES INC  
Form 10-Q  
November 14, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 10-Q**

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number:

0-22923

**INTERNATIONAL ISOTOPES INC.**

*(Exact name of registrant as specified in its charter)*

**Texas**  
*(State or other jurisdiction of  
incorporation or organization)*

**74-2763837**  
*(IRS Employer Identification Number)*

**4137 Commerce Circle**  
**Idaho Falls, Idaho, 83401**  
*(Address of principal executive offices, including zip code)*

**(208) 524-5300**  
*(Registrant's telephone number, including area code)*

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    ☒ Yes    ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    ☒ Yes    ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐  
Non-accelerated filer ☐

Accelerated filer ☐  
Smaller reporting company ☒

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    ☐  
Yes ☒ No

As of November 5, 2014, the number of shares of Common Stock, \$.01 par value, outstanding was 369,895,032.

**INTERNATIONAL ISOTOPES INC.**

**FORM 10-Q**

**For The Quarter Ended September 30, 2014**

**TABLE OF CONTENTS**

	<b><u>Page</u></b> <b><u>No.</u></b>
<b>PART I FINANCIAL INFORMATION</b>	
<u>Item 1. Financial Statements</u>	
<u>Unaudited Condensed Consolidated Balance Sheets at September 30, 2014 and December 31, 2013</u>	3
<u>Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2014 and 2013</u>	4
<u>Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2014 and 2013</u>	5
<u>Notes to Unaudited Condensed Consolidated Financial Statements</u>	6
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	14
<u>Item 4. Controls and Procedures</u>	24
<b>PART II OTHER INFORMATION</b>	
<u>Item 1A. Risk Factors</u>	25
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	25
<u>Item 6. Exhibits</u>	25
<u>Signatures</u>	26

## Part I. Financial Information

## Item 1. Financial Statements

## INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES

## Unaudited Condensed Consolidated Balance Sheets

	<b>September 30, 2014</b>	<b>December 31, 2013</b>
<b>Assets</b>		
Current assets		
Cash and cash equivalents	\$ 725,235	\$ 456,374
Accounts receivable	869,243	1,046,403
Inventories	989,587	1,478,349
Prepays and other current assets	445,509	613,795
Total current assets	3,029,574	3,594,921
Long-term assets		
Restricted certificate of deposit	203,177	204,222
Property, plant and equipment, net	2,239,139	2,271,153
Capitalized lease disposal costs, net	80,974	90,199
Investment	1,369,230	1,368,808
Patents and other intangibles, net	4,423,434	4,478,711
Total long-term assets	8,315,954	8,413,093
Total assets	\$ 11,345,528	\$ 12,008,014
<b>Liabilities and Stockholders' Equity</b>		
Current liabilities		
Accounts payable	\$ 557,857	\$ 732,449
Accrued liabilities	926,447	610,759
Current installments of notes payable	207,807	341,373
Total current liabilities	1,692,111	1,684,581
Long-term liabilities		
Convertible debt, net of debt discount	3,893,707	3,806,452
Obligation for lease disposal costs	601,036	566,369
Notes payable, net of current portion and debt discount	227,517	254,198
Mandatorily redeemable convertible preferred stock	850,000	850,000
Total long-term liabilities	5,572,260	5,477,019
Total liabilities	7,264,371	7,161,600
Stockholders' equity		
	3,694,535	3,691,314

Edgar Filing: INTERNATIONAL ISOTOPES INC - Form 10-Q

Common stock, \$0.01 par value; 750,000,000 shares  
authorized; 369,453,526 and 369,130,899 shares  
issued and outstanding respectively

Additional paid in capital	118,253,678	117,783,738
Accumulated deficit	(117,945,137)	(116,697,147)
Equity attributable to International Isotopes Inc. stockholders	4,003,076	4,777,905
Equity attributable to noncontrolling interest	78,081	68,509
Total equity	4,081,157	4,846,414
Total liabilities and stockholders' equity	\$ 11,345,528	\$ 12,008,014

See accompanying notes to the unaudited condensed consolidated financial statements.

## INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES

## Unaudited Condensed Consolidated Statements of Operations

	Three months ended		Nine months ended	
	September 30, 2014	2013	September 30, 2014	2013
Sale of product	\$ 1,985,956	\$ 1,680,696	\$ 5,743,393	\$ 5,153,534
Cost of product	1,201,482	1,056,754	3,474,605	3,161,960
Gross profit	784,474	623,942	2,268,788	1,991,574
Operating costs and expenses:				
Salaries and contract labor	384,720	404,082	1,146,444	1,272,319
General, administrative and consulting	381,599	435,734	1,309,216	1,372,284
Research and development	155,802	111,636	368,286	555,305
Total operating expenses	922,121	951,452	2,823,946	3,199,908
Net operating loss	(137,647)	(327,510)	(555,158)	(1,208,334)
Other income (expense):				
Other income (expense)	7,320	11,083	22,948	(17,049)
Equity in net income of affiliate	30,978	5,044	71,564	36,677
Interest income	98	21	491	447
Interest expense	(157,849)	(119,839)	(778,263)	(329,291)
Total other income (expense)	(119,453)	(103,691)	(683,260)	(309,216)
Net loss	(257,100)	(431,201)	(1,238,418)	(1,517,550)
Loss (income) attributable to non-controlling interest	(10,387)	7,094	(9,572)	25,341
Net loss attributable to International Isotopes Inc.	\$ (267,487)	\$ (424,107)	\$ (1,247,990)	\$ (1,492,209)
Net loss per common share - basic and diluted	\$ -	\$ -	\$ -	\$ -

Weighted average common shares outstanding - basic and diluted	369,443,913	363,502,559	369,327,455	361,989,965
---	-------------	-------------	-------------	-------------

See accompanying notes to the unaudited condensed consolidated financial statements.



## INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES

## Unaudited Condensed Consolidated Statements of Cash Flows

	Nine months ended	
	September 30,	
	2014	2013
Cash flows from operating activities:		
Net loss	\$ (1,238,418)	\$ (1,517,550)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:		
Net income in equity method investment	(71,564)	(36,677)
Depreciation and amortization	204,167	315,697
Loss on disposal of property, plant and equipment	-	40,302
Accretion of obligation for lease disposal costs	34,667	32,026
Accretion of beneficial conversion feature and debt discount	481,398	192,579
Equity based compensation	66,286	179,818
Changes in operating assets and liabilities:		
Accounts receivable	177,160	(16,179)
Prepays and other assets	168,286	81,889
Inventories	488,762	(294,125)
Accounts payable and accrued liabilities	141,096	107,038
Net cash provided by (used in) operating activities	451,840	(915,182)
Cash flows from investing activities:		
Restricted certificate of deposit	1,045	(354)
Dividends received from equity method investment	71,142	58,993
Proceeds from sale of property, plant and equipment	-	3,993
Purchase of property, plant and equipment	(107,651)	(500,025)
Net cash used in investing activities	(35,464)	(437,393)
Cash flows from financing activities:		
Proceeds from sale of stock	6,983	466,130
Proceeds from issuance of debt	-	1,060,000
Principal payments on notes payable	(154,498)	(185,120)
Net cash (used in) provided by financing activities	(147,515)	1,341,010
Net increase (decrease) in cash and cash equivalents	268,861	(11,565)
Cash and cash equivalents at beginning of period	456,374	546,143
Cash and cash equivalents at end of period	\$ 725,235	\$ 534,578
Supplemental disclosure of cash flow activities:		
Cash paid for interest	\$ 37,913	\$ 81,051

Supplemental disclosure of noncash financing and investing transactions:

Edgar Filing: INTERNATIONAL ISOTOPES INC - Form 10-Q

Increase in equity and decrease in debt for amount allocated to warrants issued with convertible debentures	\$	384,428	\$	-
Increase in equity and decrease in debt for beneficial conversion feature associated with the convertible debentures	\$	15,464	\$	-
Decrease in accrued interest through warrant exercise	\$	-	\$	100,732
Increase in notes payable through conversion of NRC payable	\$	-	\$	596,816
Increase in equity for the beneficial conversion feature associated with the convertible debentures	\$	-	\$	75,715

See accompanying notes to the unaudited condensed consolidated financial statements.

**INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES**

**Notes to Unaudited Condensed Consolidated Financial Statements**

**For the Quarter Ended September 30, 2014**

(1)

**The Company and Basis of Presentation**

International Isotopes Inc. (INIS) was incorporated in Texas in November 1995. The accompanying unaudited condensed consolidated financial statements are presented in conformity with accounting principles generally accepted in the United States of America (GAAP) and include all operations and balances of the Company and its wholly-owned subsidiaries, International Isotopes Idaho, Inc., a Texas corporation, International Isotopes Fluorine Products, Inc., an Idaho corporation, and International Isotopes Transportation Services, Inc., an Idaho corporation. The unaudited condensed consolidated financial statements also include the accounts of INIS's 50% owned joint venture, TI Services, LLC, which is located in Youngstown, Ohio. The Company's headquarters and all operations, with the exception of TI Services, LLC, are located in Idaho Falls, Idaho.

*Nature of Operations* INIS and its subsidiaries and joint venture (collectively, the Company, we, our or manufacture a full range of nuclear medicine calibration and reference standards, a wide range of products including cobalt teletherapy sources, and a varied selection of radioisotopes and radiochemicals for medical research, and clinical devices. The Company holds several patents for a fluorine extraction process that it expects to use in conjunction with a proposed commercial depleted uranium de-conversion facility, and provides a host of transportation, recycling, and processing services on a contract basis for clients. The Company's business consists of six major business segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Fluorine Products, Radiological Services, and Transportation.

With the exception of certain unique products, the Company's normal operating cycle is considered to be one year. Due to the time required to produce some cobalt products, the Company's operating cycle for those products is considered to be three years. All assets expected to be realized in cash or sold during the normal operating cycle of business are classified as current assets.

*Principles of Consolidation* The unaudited condensed consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries and its 50% owned joint venture, TI Services, LLC. All intercompany accounts and transactions have been eliminated in consolidation.

*Interim Financial Information* The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments and reclassifications considered necessary in order to make the financial statements not misleading and for a fair and comparable presentation have been included and are of a normal recurring nature. Operating results for the nine-month period ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. The accompanying financial statements should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on March 28, 2014.

*Recent Accounting Standards* - In May 2014, the FASB issued authoritative guidance for revenue and contracts with customers. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps:

Step 1: Identify the contract(s) with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

An entity should disclose sufficient information to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Qualitative and quantitative information is required about:

1. Contracts with customers-including revenue and impairments recognized, disaggregation of revenue, and information about contract balances.
2. Significant judgments and changes in judgments-determining the timing of satisfaction of performance obligations (over time or at a point in time), and determining the transaction price and amounts allocated to performance obligations.
3. Assets recognized from the costs to obtain or fulfill a contract.

For public entities, the amendments in this Update are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early adoption is not permitted. The Company has not yet determined what effect this standard will have on its results of operations.

In June 2014, the FASB issued authoritative guidance for stock based compensation. The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance as it relates to awards with performance conditions that affect vesting to account for such awards. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. As indicated in the definition of vest, the stated vesting period (which includes the period in which the performance target could be achieved) may differ from the requisite service period. The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The Company has not yet determined what effect this standard will have on its results of operations

(2)

Current Developments and Liquidity

*Business Condition* Since inception, the Company has suffered substantial losses. During the nine-month period ended September 30, 2014, the Company reported a net loss of \$1,247,990, net of non-controlling interest loss, and net cash provided by operating activities of \$451,840. During the same period in 2013, the Company reported a net loss of \$1,492,209, net of non-controlling interest loss, and net cash used in operating activities of \$915,182.

The Company has made significant investments in the design, planning and construction of a large scale uranium de-conversion and fluorine extraction facility, a project the Company started in 2004. Since beginning its efforts to design and build this proposed de-conversion facility, the Company acquired seven patents for the Fluorine Extraction Process ( FEP ) and later designed, built, and operated an FEP pilot plant to produce a fluoride gas from de-conversion of uranium tetrafluoride. At the completion of testing in 2013, the pilot plant was shut down. In October 2012, the Company obtained a Nuclear Regulatory Commission ( NRC ) construction and operating license for the planned de-conversion facility which is a forty (40) year operating license and is the first commercial license of this type issued in the U.S. There are no other companies with a similar license application under review by the NRC. Therefore, the NRC license represents a significant competitive barrier and the Company believes that it provides it with a very valuable asset.

Since the start of this project there have been several changes in the nuclear industry that have caused the Company to place this de-conversion project on hold. When the Company began pursuing this project there were three companies planning for construction of new commercial uranium enrichment plants in the U.S. and a fourth company using the Silex laser separation technology for enrichment. The Company was communicating with all of these companies for possible de-conversion agreements to process their tails and was successful in obtaining a de-conversion service agreement with URENCO USA (UUSA) that would use approximately 50% of the installed processing capacity of its proposed de-conversion facility. While the agreement with UUSA remains in place the milestone dates in the agreement for the Company to have an operating de-conversion facility have passed. UUSA has not indicated they intend to terminate the agreement at this time. Instead UUSA and the Company plan to revise the agreement milestone dates at a future time once the Company has a firmer idea of the schedule for resumption of engineering and construction of the project. Plans to obtain additional contracts with the other enrichment companies in order to commit 100% of the planned facility's capacity have been delayed because of the slowdown in nuclear industry growth. Having contracts in place for the full plant capacity is necessary for the Company to obtain financing for the project and it believes that one or more of these companies are likely to resume construction plans on a new enrichment facility within the next few years. When these plans do resume, the Company will once again begin contract talks to commit the remaining capacity for its planned de-conversion facility and continue efforts to obtain project financing to proceed with the design and construction of the facility. It is also expected that the Company will be able to revise its contract dates with UUSA once one of these other enrichment companies resumes construction planning. Therefore, in the fourth quarter of 2013, the Company placed most of the work on that project on hold until additional contracts for de-conversion service could be secured and financing obtained for the project. During the nine-month period ended September 30, 2014, the Company incurred costs of approximately \$307,000 to maintain licenses and other necessary project investments. During the same nine-month period in 2013, the Company incurred costs of approximately \$685,000 for planning and development activities on the project.

In the meantime, the Company is renewing its focus upon its long-standing core business segments and working to reduce operating costs as well as create new business opportunities within those segments. The results of these efforts have led to positive cash flow produced by operating activities for the first nine months of 2014. While there can be no assurances that this positive cash flow from operations will continue the Company will continue to work towards that goal and in achieving profitability based upon the performance of our current business segments. The Company believes there are significant future opportunities for growth within the radiochemical, cobalt products, and field services segments and will be exploring those opportunities to expand business and revenue within those segments. The Company will make public announcements of those developments as agreements are put in place to secure those opportunities.

(3)

Net Loss Per Common Share - Basic and Diluted

For the nine months ended September 30, 2014, the Company had 16,450,000 stock options outstanding, 42,257,951 warrants outstanding, and 425,000 shares of Series B redeemable convertible preferred stock outstanding that were not included in the computation of diluted loss per common share because they would be anti-dilutive.

For the nine months ended September 30, 2013, the Company had 16,450,000 stock options outstanding, 19,757,951 warrants outstanding, and 425,000 shares of Series B redeemable convertible preferred stock outstanding that were not included in the computation of diluted loss per common share because they would be anti-dilutive.



(4)

## Investment

The Company owns a 24.5% interest in RadQual, LLC (RadQual), with which the Company has an exclusive manufacturing agreement for nuclear medicine products. The 24.5% ownership of RadQual has a balance of \$1,369,230 and is reported as an asset at September 30, 2014. For the nine months ended September 30, 2014, member distributions from RadQual totaled \$71,142 and were recorded as a reduction of the investment, and for the same period in 2013, member distributions totaled \$58,993. During the nine months ended September 30, 2014 and 2013, earnings allocated to the Company from RadQual totaled \$71,564 and \$36,677, respectively. These allocated earnings were recorded as equity in net income of affiliate on the Company's condensed consolidated statements of operations.

At September 30, 2014 and 2013, the Company had receivables from RadQual in the amount of \$391,621 and \$439,641, respectively, which are recorded as part of accounts receivable on the Company's condensed consolidated balance sheets. For the nine months ended September 30, 2014 and 2013, the Company had revenue from RadQual in the amount of \$2,242,843 and \$2,360,178, respectively, which is recorded as sale of product on the Company's condensed consolidated statements of operations.

(5)

## Inventories

Inventories consisted of the following at September 30, 2014 and December 31, 2013:

	<b>September 30,</b>		<b>December 31,</b>	
	<b>2014</b>		<b>2013</b>	
Raw materials	\$	91,555	\$	247,667
Work in progress		881,595		1,206,708
Finished goods		16,437		23,974
	\$	989,587	\$	1,478,349

Work in progress includes cobalt-60 which is located in the U.S. federal government's Advanced Test Reactor (ATR) located outside of Idaho Falls, Idaho. The cobalt is at various stages of production. At September 30, 2014 and December 31, 2013, the cobalt had a carrying value of \$691,501 and \$957,221, respectively, which is based on accumulated costs allocated to cobalt targets depending on the length of time the cobalt has been processed in the ATR.

(6)

Stockholders Equity, Options and Warrants

#### Employee Stock Purchase Plan

During the nine months ended September 30, 2014 and 2013, the Company issued 154,767 and 63,646 shares of common stock, respectively, to employees for proceeds of \$6,983 and \$8,241, respectively. All of these shares were issued in accordance with the Company's employee stock purchase plan.

#### Stock-Based Compensation Plans

*Employee/Director Grants* - The Company accounts for issuances of stock-based compensation to employees by recognizing, as compensation expense, the cost of employee services received in exchange for the equity awards. The compensation expense is based on the grant date fair value of the award. Stock option compensation expense is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).

*Non-Employee Grants* - The Company accounts for its issuances of stock-based compensation to non-employees by measuring the value of any awards that were vested and non-forfeitable at their date of issuance based on the grant date fair value of the award. The non-vested portion of awards that are subject to the future performance of the counterparty are adjusted at each reporting date to their fair values based upon the then current market value of the Company's stock and other assumptions that management believes are reasonable.

Edgar Filing: INTERNATIONAL ISOTOPES INC - Form 10-Q

Option awards outstanding as of September 30, 2014, and changes during the nine months ended September 30, 2014, were as follows:

<b>Fixed Options</b>	<b>Shares</b>	<b>Weighted Average Exercise Price</b>	<b>Weighted Average Remaining Contractual Life</b>	<b>Aggregate Intrinsic Value</b>
Outstanding at December 31, 2013	16,450,000	\$ 0.09		
Granted	-			
Exercised	-			
Forfeited	-			
Outstanding at September 30, 2014	16,450,000	0.09	3.0	\$ -
Exercisable at September 30, 2014	14,887,500	\$ 0.09	3.4	\$ -

The intrinsic value of outstanding and exercisable shares is based on the closing price of the Company's common stock of \$0.04 per share on September 30, 2014, the last trading day of the quarter. The intrinsic value of exercisable shares is based on the closing price of the Company's common stock on the day of exercise with a weighted-average price of \$0.09 per share.

As of September 30, 2014, there was approximately \$59,510 of unrecognized compensation expense related to stock options that will be recognized over a weighted-average period of 1.5 years.

Total stock-based compensation expense for the nine months ended September 30, 2014 and 2013 was \$66,286 and \$179,818, respectively.

Pursuant to an employment agreement with its CEO, the Company issued 280,000 fully vested shares of common stock in February 2014, under the Company's 2006 Equity Incentive Plan. The number of shares awarded was based on a \$28,000 stock award using a price of \$0.10 per share. The agreement states that the number of shares issued will be based on the average closing price of common stock for the 20 trading days prior to issue date but not less than \$0.10 per share. Compensation expense recorded pursuant to this stock grant was \$16,800, which was determined by multiplying the number of shares awarded by the closing price of the common stock on February 27, 2014, which was \$0.06 per share. The Company withheld 112,140 shares of common stock to satisfy the employee's payroll tax liabilities. The net shares issued on February 28, 2014, totaled 167,860.

#### Warrants

Warrants outstanding at September 30, 2014, and changes during the nine months ended September 30, 2014, were as follows:

Warrants	
Outstanding at December 31, 2013	27,257,951
Issued	15,000,000
Exercised	-
Forfeited	-
Outstanding at September 30, 2014	42,257,951

Pursuant to the promissory note issued to the Company's Chairman of the Board and one of the Company's major shareholders as discussed below, an aggregate of 15,000,000 additional warrants were issued on June 30, 2014, as a condition of extending the due date of the promissory note from June 30, 2014 to December 31, 2017.

(7) Debt

In June 2014, the Company renegotiated the terms of a promissory note totaling \$500,000 from the Company's Chairman of the Board and one of the Company's major shareholders (the "Lenders"). The promissory note bears interest at 6% and originally matured on June 30, 2014. At any time, the Lenders can elect to have any or all of the principal and accrued interest under the promissory note repaid in the form of shares of the Company's common stock, at a rate based on the average closing price of the Company's common stock for the 20 trading days preceding the maturity of the prepayment date. In connection with the promissory note, each Lender was issued 5,000,000 warrants to purchase shares of the Company's common stock. The fair value of the warrants was \$383,025 and was recorded as a debt discount and was amortized to interest expense over the initial six-month life of the promissory note. The warrants are immediately exercisable. The fair value of the warrants was determined using the Black-Scholes Option Pricing Model and was calculated using the following assumptions: risk free interest rate of 1.33%, expected dividend yield rate of 0%, expected volatility of 78.9%, an expected life of 5 years.

Pursuant to a modification to the loan made June 30, 2014, the maturity date was extended to December 31, 2017, and each Lender was granted an additional 7,500,000 warrants to purchase shares of the Company's common stock at \$0.06 per share. The warrants were immediately exercisable. The fair value of these warrants was \$384,428 and was recorded as a debt discount and will be amortized to interest expense over the new life of the promissory note. The fair value of the warrants was determined using the Black-Scholes Option Pricing Model and was calculated using the following assumptions: risk free interest rate of 1.62%, expected dividend yield rate of 0%, expected volatility of 69.47%, an expected life of 4.5 years. The Company calculated a beneficial conversion feature of \$15,464 which will be accreted to interest expense over the new life of the note.

(8)

Commitments and Contingencies

Dependence on Third Parties

The production of HSA Cobalt is dependent upon the U.S. Department of Energy (DOE), and its prime operating contractor, which controls the reactor and laboratory operations at the U.S. federal government's Advanced Test Reactor (ATR) located outside of Idaho Falls, Idaho. The Company has been in negotiations with the DOE, since 2012, to determine further irradiation of in-process targets and to start the irradiation of new cobalt targets. On October 2, 2014, the Company signed a ten year contract with the DOE for the irradiation of cobalt targets for the production of cobalt-60. The Company will be able to purchase cobalt targets for a fixed price per target and with an annual 5% escalation in price. The contract term is October 1, 2014, through September 30, 2024. However, the DOE may end the contract if it determines termination is necessary for the national defense, security or environmental safety of the United States.

Nuclear Medicine Reference and Calibration Standard manufacturing is conducted under an exclusive contract with RadQual, which in turn has an agreement in place with several companies for distributing the products. A loss of any of these customers or suppliers could adversely affect operating results by causing a delay in production or a possible loss of sales.

Historically, the majority of the radiochemical products sold by the Company were done so through a supply agreement with a single entity. In September 2014, the Company ended this arrangement and began direct sales to its customers of all radiochemical products.

Contingencies

Because all of the Company's business segments involve radioactive material, the Company is required to have an operating license from the NRC and specially trained staff to handle these materials. The Company has an NRC operating license and has amended this license many times to increase the amount of material permitted within its facility and change the descriptions of scope of work permitted both in the facility and by the Company in other locations. Additional processing capabilities and license amendments could be implemented that would permit processing of other reactor-produced radioisotopes by the Company. The current license does not restrict the volume of business operation performed or projected to be performed in the upcoming year. The financial assurance required by the NRC has been provided for with a surety bond issued by Argonaut Insurance Company. This surety bond will terminate in November 2014 and will be replaced with a letter of credit which will name the NRC as beneficiary. The Company has placed \$203,177 into a certificate of deposit as required by the terms of the surety bond and, at the termination of the bond these funds will be used to support the new letter of credit which will replace the surety bond. At September 30, 2014, the restricted certificate of deposit totaled \$203,177.

(9) Subsequent Events

In October 2014, in accordance with the Company's employee stock purchase plan, the Company issued 42,105 shares of common stock to employees in exchange for proceeds of \$1,432.

On October 1, 2014, the Company made interest payments to holders of its convertible debentures that were issued February 2012. According to the terms of the convertible debentures, the interest payment was for interest accrued on principal amounts held by investors from October 1, 2013 through September 30, 2014. The amount of interest paid in cash to investors was \$229,370 in the aggregate. In addition, two investors opted to receive shares of the Company's common stock in lieu of cash interest payments. As a result, 399,401 shares of common stock were issued in exchange for \$15,976 of accrued interest due.

On October 2, 2014, the Company entered into a ten year agreement with the DOE for the irradiation of cobalt targets for the production of cobalt-60. The agreement stipulates that the Company will be able to purchase cobalt targets at a fixed price per target with an annual 5% escalation in price.

On October 27, 2014, the Compensation Committee of the Company's Board of Directors approved the re-pricing of an aggregate of 14,500,000 outstanding stock options held by executive officers and members of the Board, which had original exercise prices of either \$0.07 or \$0.08 per share. The Compensation Committee lowered the exercise price per share to \$0.035 for each option, which was the fair market value of the Company's stock on October 27, 2014.

In addition, on October 27, 2014, the Compensation Committee granted an aggregate of 8,100,000 incentive stock options to executive officers and employees with an exercise price of \$0.035 per share. Also, the Compensation Committee granted 400,000 nonqualified stock options to consultants and 3,000,000 nonqualified stock options to members of the Board. All of the stock options were granted with an exercise price of \$0.035 per share, vest over a period of two years, and expire on October 27, 2024.

All of the above stock options were granted pursuant to the terms of the Company's 2006 Equity Incentive Plan.



(10)

## Segment Information

The Company has six reportable segments which include: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Fluorine Products, Radiological Services, and Transportation. Information regarding the operations and assets of these reportable business segments is contained in the following table:

	Three months ended		Nine months ended	
	September 30,		September 30,	
	2014	2013	2014	2013
Sale of Product				
Radiochemical Products	\$ 427,588	\$ 450,285	\$ 1,306,980	\$ 1,316,909
Cobalt Products	558,168	332,295	1,252,216	777,424
Nuclear Medicine Standards	924,143	736,238	2,536,732	2,455,987
Radiological Services	65,057	143,380	565,540	484,416
Fluorine Products	-	-	-	-
Transportation	11,000	18,498	81,925	118,798
Total Segments	1,985,956	1,680,696	5,743,393	5,153,534
Corporate revenue	-	-	-	-
Total Consolidated	\$ 1,985,956	\$ 1,680,696	\$ 5,743,393	\$ 5,153,534

	Three months ended		Nine months ended	
	September 30,		September 30,	
	2014	2013	2014	2013
Depreciation and Amortization				
Radiochemical Products	\$ 1,687	\$ 9,511	\$ 5,487	\$ 28,098
Cobalt Products	19,562	18,572	59,431	62,226
Nuclear Medicine Standards	3,718	5,213	15,445	15,642
Radiological Services	9,227	1,580	22,281	5,258
Fluorine Products	27,347	32,794	81,838	154,936
Transportation	1,110	3,314	5,669	9,942
Total Segments	62,651	70,984	190,151	276,102
Corporate depreciation and amortization	4,624	30,456	14,016	39,595
Total Consolidated	\$ 67,275	\$ 101,440	\$ 204,167	\$ 315,697

	Three months ended		Nine months ended	
	September 30,		September 30,	
	2014	2013	2014	2013
Segment Income (Loss)				
Radiochemical Products	\$ 88,510	\$ 75,153	\$ 269,112	\$ 198,949
Cobalt Products	269,913	109,987	501,175	179,744
Nuclear Medicine Standards	172,544	134,699	485,441	449,366
Radiological Services	16,387	19,749	191,478	219,712
Fluorine Products	(101,368)	(127,989)	(307,705)	(685,134)
Transportation	(11,402)	(5,702)	(18,480)	338

Edgar Filing: INTERNATIONAL ISOTOPES INC - Form 10-Q

Total Segments	434,584	205,897	1,121,020	362,974
Corporate loss	(702,071)	(630,004)	(2,369,010)	(1,855,183)
Net Loss	\$ (267,487)	\$ (424,107)	\$ (1,247,990)	\$ (1,492,209)

**Three months ended**

**Nine months ended**

	<b>September 30,</b>		<b>September 30,</b>	
Expenditures for Segment Assets	<b>2014</b>	<b>2013</b>	<b>2014</b>	<b>2013</b>
Radiochemical Products	\$ 403	\$ 4,356	\$ 53,320	\$ 4,356
Cobalt Products	3,883	(6,668)	40,932	-
Nuclear Medicine Standards	-	-	527	3,540
Radiological Services	-	72,292	2,632	95,612
Fluorine Products	4,504	126,983	(1,047)	393,580
Transportation	-	-	-	-
Total Segments	8,790	196,963	96,364	497,088
Corporate purchases	-	-	11,287	2,937
Total Consolidated	\$ 8,790	\$ 196,963	\$ 107,651	\$ 500,025

	<b>September 30,</b>	<b>December 31,</b>
Segment Assets	<b>2014</b>	<b>2013</b>
Radiochemical Products	\$ 249,134	\$ 153,305
Cobalt Products	1,034,872	1,574,603
Nuclear Medicine Standards	555,932	573,389
Radiological Services	384,255	608,949
Fluorine Products	6,020,190	6,093,151
Transportation	7,195	12,864
Total Segments	8,251,578	9,016,261
Corporate assets	3,093,950	2,991,753
Total Consolidated	\$ 11,345,528	\$ 12,008,014

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

*This Quarterly Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding prospects for additional commercial uranium enrichment projects, the Company's ability to secure contracts and raise capital for the planned de-conversion facility, the competitive barrier posed by the Nuclear Regulatory Commission (NRC) license and its asset value, future positive cash flow from operations, the Company's ability to achieve profitability, the ability to continue irradiation of the in-process cobalt targets, positive growth projection for TI Services, LLC, growth in the revenue of the radiochemical, radiological and transportation segments, are forward-looking. Forward-looking statements reflect management's current expectations, plans or projections. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Certain risks and uncertainties that could cause our actual results to differ significantly from management's expectations are described in the risk factors set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission (SEC) on March 28, 2014, in this report and in the other reports we file with the SEC. These factors describe some but not all of the factors that could cause actual results to differ significantly from management's expectations. We will not publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are urged, however, to review the other factors set forth in reports that we file from time to time with the SEC.*

### BUSINESS OVERVIEW

International Isotopes Inc. and its subsidiaries and joint venture (collectively, the Company, we, our, or us) manufacture a full range of nuclear medicine calibration and reference standards, a wide range of products including cobalt teletherapy sources, and a varied selection of radioisotopes and radiochemicals for medical research, and clinical devices. We hold several patents for a fluorine extraction process that we are planning to use in conjunction with a planned new commercial depleted uranium de-conversion facility, and provide a host of transportation, recycling, and processing services on a contract basis for clients. Our business consists of the following six major business segments:

**Nuclear Medicine Standards.** Our Nuclear Medicine Standards segment consists of the manufacture of sources and standards associated with SPECT (Single Photon Emission Computed Tomography), patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry.

**Cobalt Products.** Our Cobalt Products segment includes the production of bulk cobalt (cobalt-60), fabrication of cobalt capsules for teletherapy or irradiation devices, and recycling of expended cobalt sources.

*Radiochemical Products.* Our Radiochemical Products segment includes production and distribution of various isotopically pure radiochemicals for medical, industrial, or research applications. These products are either directly produced by us or are purchased in bulk from other producers and distributed by us in customized packages and chemical forms tailored to meet customer requirements.

*Fluorine Products.* We established the Fluorine Products segment in 2004 to support production and sale of the gases produced using our Fluorine Extraction Process (FEP). We operated the pilot facility to develop production processes for various high purity products and to test methods of scaling up the size of production operations in support of the planned de-conversion facility in New Mexico. In 2013, we shut down the pilot plant facility and placed further engineering work on the New Mexico facility on hold. Further activity within this segment will be deferred until market conditions change and justify resuming planning for the facility.

*Radiological Services.* Our Radiological Services segment consists of a wide variety of miscellaneous services, including processing gemstones which have undergone irradiation for color enhancement, radiological engineering consultant services, field service activities, and contract shipping services for large quantities of radioactive materials.

*Transportation.* Our Transportation segment was established in 2006 to provide transportation of our own products (such as cobalt) and to offer for hire transportation services of hazardous and non-hazardous cargo materials. This business segment provides us with considerable savings for the transportation of our products and produces a small revenue stream by providing transportation of products for other companies.

## RESULTS OF OPERATIONS

### *Three Months Ended September 30, 2014 Compared to Three Months Ended September 30, 2013*

Revenue for the three months ended September 30, 2014 was \$1,985,956, as compared to \$1,680,696 for the same period in 2013, an overall increase of \$305,260, or approximately 19%. The following table presents a period-to-period comparison of total revenue by segment with further discussion of the performance of each business segment provided in the following paragraphs.

	<b>For the three-</b>	<b>For the three-</b>		
	<b>months ended</b>	<b>months ended</b>		
	<b>September 30,</b>	<b>September 30,</b>		
	<b>2014</b>	<b>2013</b>	<b>\$ change</b>	<b>% change</b>
Sale of Product				
Radiochemical Products	\$ 427,588	\$ 450,285	\$ (22,697)	-5%
Cobalt Products	558,168	332,295	225,873	68%
Nuclear Medicine Standards	924,143	736,238	187,905	26%
Radiological Services	65,057	143,380	(78,323)	-55%
Fluorine Products	-	-	-	0%
Transportation	11,000	18,498	(7,498)	-41%
Total Segments	1,985,956	1,680,696	305,260	19%
Corporate revenue	-	-	-	0%
Total Consolidated	\$ 1,985,956	\$ 1,680,696	\$ 305,260	19%

Gross profit for the three months ended September 30, 2014 was \$784,474, compared to \$623,942 for the same period in 2013. This represents an increase of \$160,532, or approximately 26%. Cost of sales increased to \$1,201,482 for the three months ended September 30, 2014 from \$1,056,754 for the same period in 2013. This is an increase of \$144,728, or approximately 14% and was the result of increased purchases of materials and direct labor costs to support increased production and overall sales. Our gross profit percentage was up slightly to 40% for the three months ended September 30, 2014, from 37% for the same period in 2013, as a result of combined increased revenue coupled with the relative decrease in cost of sales as a percentage of total sales. Segment performance in this area is discussed in further detail below.

The following table presents gross profit data for each of our business segments for the three months ended September 30, 2014 and 2013:

<b>For the three-</b>	<b>% of</b>	<b>For the three-</b>	<b>% of</b>
<b>months ended</b>	<b>Total</b>	<b>months ended</b>	<b>Total</b>
<b>September 30,</b>	<b>Sales</b>	<b>September 30,</b>	<b>Sales</b>